4//SEC Filing
Calabrese Jeffrey 4
Accession 0001209191-22-058160
CIK 0001337553other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 4:34 PM ET
Size
10.6 KB
Accession
0001209191-22-058160
Insider Transaction Report
Form 4
Calabrese Jeffrey
Vice President of Finance
Transactions
- Disposition to Issuer
Common Stock
2022-11-21$15.25/sh−18,585$283,421→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2022-11-21$4.23/sh−6,257$26,467→ 0 totalExercise: $11.02Exp: 2031-11-01→ Common Stock (6,257 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-11-21$6.89/sh−20,774$143,133→ 0 totalExercise: $8.36Exp: 2032-07-01→ Common Stock (20,774 underlying)
Footnotes (2)
- [F1]Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
- [F2]Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Documents
Issuer
AERIE PHARMACEUTICALS INC
CIK 0001337553
Entity typeother
Related Parties
1- filerCIK 0001892279
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 4:34 PM ET
- Size
- 10.6 KB